{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:43:12Z","timestamp":1787668992084,"version":"build-2736575974"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40257-019-00465-3","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T12:02:30Z","timestamp":1564228950000},"page":"807-815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Ocular Co-Morbidities of Atopic Dermatitis. Part II: Ocular Disease Secondary to Treatments"],"prefix":"10.1007","volume":"20","author":[{"given":"Kristen M.","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerami D.","family":"Seitzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle M.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,27]]},"reference":[{"key":"465_CR1","doi-asserted-by":"publisher","unstructured":"Beck KM, Seitzman G, Yang EJ, Sanchez IM, Liao W. Ocular comorbidities of atopic dermatitis. Part I: associated ocular diseases. Am J Clin Dermatol. In Press. \nhttps:\/\/doi.org\/10.1007\/s40257-019-00455-5\n\n.","DOI":"10.1007\/s40257-019-00455-5"},{"issue":"37","key":"465_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta4370","volume":"4","author":"C Hoare","year":"2000","unstructured":"Hoare C, Po LWA, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1\u2013191.","journal-title":"Health Technol Assess."},{"issue":"2","key":"465_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaci.2012.12.672","volume":"131","author":"L Schneider","year":"2013","unstructured":"Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J, et al. Atopic dermatitis: a\u00a0practice parameter update 2012. J Allergy Clin Immunol. 2013;131(2):295\u20139.e27.","journal-title":"J Allergy Clin Immunol."},{"issue":"2","key":"465_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.clindermatol.2015.11.012","volume":"34","author":"A Turno-Kr\u0119cicka","year":"2016","unstructured":"Turno-Kr\u0119cicka A, Grzybowski A, Misiuk-Hoj\u0142o M, Patryn E, Czajor K, Nita M. Ocular changes induced by drugs commonly used in dermatology. Clin Dermatol. 2016;34(2):129\u201337.","journal-title":"Clin Dermatol"},{"issue":"3","key":"465_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/ajd.12292","volume":"56","author":"BS Daniel","year":"2015","unstructured":"Daniel BS, Orchard D. Ocular side-effects of topical corticosteroids: what a dermatologist needs to know. Australas J Dermatol. 2015;56(3):164\u20139.","journal-title":"Australas J Dermatol"},{"issue":"Pt 5","key":"465_CR6","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/eye.1993.152","volume":"7","author":"RK Aggarwal","year":"1993","unstructured":"Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S. Extensive visual loss with topical facial steroids. Eye (Lond). 1993;7(Pt 5):664\u20136.","journal-title":"Eye (Lond)."},{"issue":"2","key":"465_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1442-9071.2004.00787.x","volume":"32","author":"HM Garrott","year":"2004","unstructured":"Garrott HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. Clin Exp Ophthalmol. 2004;32(2):224\u20136.","journal-title":"Clin Exp Ophthalmol."},{"issue":"4","key":"465_CR8","first-page":"222","volume":"34","author":"GW Thoe Schwartzenberg","year":"1999","unstructured":"Thoe Schwartzenberg GW, Buys YM. Glaucoma secondary to topical use of steroid cream. Can J Ophthalmol. 1999;34(4):222\u20135.","journal-title":"Can J Ophthalmol."},{"key":"465_CR9","first-page":"2462","volume":"44","author":"A Michaeli-Cohen","year":"1998","unstructured":"Michaeli-Cohen A, Neudorfer M, Loewenstein A, Lazar M, Geyer O. Case report: visual loss caused by facial steroids. Can Fam Physician. 1998;44:2462\u20133.","journal-title":"Can Fam Physician"},{"issue":"6","key":"465_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1365-2230.2004.01610.x","volume":"29","author":"D Sahni","year":"2004","unstructured":"Sahni D, Darley CR, Hawk JL. Glaucoma induced by periorbital topical steroid use\u2014a rare complication. Clin Exp Dermatol. 2004;29(6):617\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"465_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/0141076809701009","volume":"97","author":"JJ Ross","year":"2004","unstructured":"Ross JJ, Jacob A, Batterbury M. Facial eczema and sight-threatening glaucoma. J R Soc Med. 2004;97(10):485\u20136.","journal-title":"J R Soc Med"},{"issue":"2","key":"465_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2133.1976.tb00830.x","volume":"95","author":"RB Cubey","year":"1976","unstructured":"Cubey RB. Glaucoma following the application of corticosteroid to the skin of the eyelids. Br J Dermatol. 1976;95(2):207\u20138.","journal-title":"Br J Dermatol"},{"issue":"9","key":"465_CR13","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/archderm.1976.01630330080032","volume":"112","author":"C Zugerman","year":"1976","unstructured":"Zugerman C, Saunders D, Levit F. Glaucoma from topically applied steroids. Arch Dermatol. 1976;112(9):1326.","journal-title":"Arch Dermatol"},{"issue":"6","key":"465_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2165\/00002512-199915060-00004","volume":"15","author":"RC Tripathi","year":"1999","unstructured":"Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and glaucoma risk. Drugs Aging. 1999;15(6):439\u201350.","journal-title":"Drugs Aging"},{"issue":"2","key":"465_CR15","first-page":"163","volume":"17","author":"R Jones 3rd","year":"2006","unstructured":"Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17(2):163\u20137.","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"465_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jaad.2010.01.035","volume":"64","author":"IM Haeck","year":"2011","unstructured":"Haeck IM, Rouwen TJ, Timmer-de Mik L, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. J Am Acad Dermatol. 2011;64(2):275\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"465_CR17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.alit.2018.01.004","volume":"67","author":"R Tamagawa-Mineoka","year":"2018","unstructured":"Tamagawa-Mineoka R, Yasuoka N, Ueta M, Katoh N. Influence of topical steroids on intraocular pressure in patients with atopic dermatitis. Allergol Int. 2018;67(3):388\u201391.","journal-title":"Allergol Int."},{"issue":"2","key":"465_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jaad.2010.01.035","volume":"64","author":"IM Haeck","year":"2011","unstructured":"Haeck IM, Rouwen TJ, Timmer-de Mik L, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. J t Am Acad Dermatol. 2011;64(2):275\u201381.","journal-title":"J t Am Acad Dermatol."},{"key":"465_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001320","author":"MM Maeng","year":"2019","unstructured":"Maeng MM, De Moraes CG, Winn BJ, Dagi LRG. Effect of topical periocular steroid use on intraocular pressure: a retrospective analysis. Ophthalmic Plast Reconstr Surg. 2019. \nhttps:\/\/doi.org\/10.1097\/IOP.0000000000001320\n\n. (Epub 2019 Feb 4).","journal-title":"Ophthalmic Plast Reconstr Surg."},{"issue":"9","key":"465_CR20","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/IJG.0000000000000069","volume":"24","author":"K Takakuwa","year":"2015","unstructured":"Takakuwa K, Hamanaka T, Mori K, Chin S, Shinmei Y, Funaki T, et al. Atopic glaucoma: clinical and pathophysiological analysis. J Glaucoma. 2015;24(9):662\u20138.","journal-title":"J Glaucoma"},{"issue":"2","key":"465_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5005\/jp-journals-10028-1226","volume":"11","author":"S Phulke","year":"2017","unstructured":"Phulke S, Kaushik S, Kaur S, Pandav S. Steroid-induced glaucoma: an avoidable irreversible blindness. J Curr Glaucoma Pract. 2017;11(2):67\u201372.","journal-title":"J Curr Glaucoma Pract."},{"issue":"4","key":"465_CR22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/archopht.1963.00960050484010","volume":"70","author":"MF Armaly","year":"1963","unstructured":"Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70(4):482\u201391.","journal-title":"Arch Ophthalmol."},{"issue":"18","key":"465_CR23","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901\u201311.","journal-title":"JAMA"},{"issue":"1","key":"465_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","volume":"71","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section\u00a02. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116\u201332.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"465_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0733-8635(18)30318-8","volume":"10","author":"L Renfro","year":"1992","unstructured":"Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10(3):505\u201312.","journal-title":"Dermatol Clin"},{"issue":"5","key":"465_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/jop.2006.0067","volume":"23","author":"ER James","year":"2007","unstructured":"James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007;23(5):403\u201320.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"10","key":"465_CR27","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1346-8138.1999.tb02068.x","volume":"26","author":"H Taniguchi","year":"1999","unstructured":"Taniguchi H, Ohki O, Yokozeki H, Katayama I, Tanaka A, Kiyosawa M, et al. Cataract and retinal detachment in patients with severe atopic dermatitis who were withdrawn from the use of topical corticosteroid. J Dermatol. 1999;26(10):658\u201365.","journal-title":"J Dermatol"},{"issue":"2","key":"465_CR28","first-page":"238","volume":"99","author":"H Katsushima","year":"1995","unstructured":"Katsushima H. Corticosteroid-induced glaucoma following treatment of the periorbital region [in Japanese]. Nippon Ganka Gakkai Zasshi. 1995;99(2):238\u201343.","journal-title":"Nippon Ganka Gakkai Zasshi."},{"issue":"7","key":"465_CR29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.ophtha.2009.12.003","volume":"117","author":"JE Thorne","year":"2010","unstructured":"Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117(7):1436\u201341.","journal-title":"Ophthalmology"},{"issue":"1","key":"465_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0886-3350(99)80018-2","volume":"25","author":"Y Nagaki","year":"1999","unstructured":"Nagaki Y, Hayasaka S, Kadoi C. Cataract progression in patients with atopic dermatitis. J Cataract Refract Surg. 1999;25(1):96\u20139.","journal-title":"J Cataract Refract Surg."},{"issue":"8","key":"465_CR31","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1001\/jamaophthalmol.2018.2166","volume":"136","author":"HS Jeon","year":"2018","unstructured":"Jeon HS, Choi M, Byun SJ, Hyon JY, Park KH, Park SJ. Association of pediatric atopic dermatitis and cataract development and surgery. JAMA Ophthalmol. 2018;136(8):912\u20138.","journal-title":"JAMA Ophthalmol."},{"key":"465_CR32","first-page":"519","volume":"66","author":"RB Oglesby","year":"1961","unstructured":"Oglesby RB, Black RL, Von Sallmann L, Bunim JJ. Cataracts in rheumatoid arthritis patients treated with corticosteroids. Description and differential diagnosis. Arch Ophthalmol. 1961;66:519\u201323.","journal-title":"Description and differential diagnosis. Arch Ophthalmol."},{"issue":"6","key":"465_CR33","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/S0161-6420(94)31219-X","volume":"101","author":"C Oka","year":"1994","unstructured":"Oka C, Ideta H, Nagasaki H, Watanabe K, Shinagawa K. Retinal detachment with atopic dermatitis similar to traumatic retinal detachment. Ophthalmology. 1994;101(6):1050\u20134.","journal-title":"Ophthalmology"},{"issue":"2","key":"465_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2500\/aap.2015.36.3827","volume":"36","author":"PA Ricketti","year":"2015","unstructured":"Ricketti PA, Unkle DW, Cleri DJ, Prenner JL, Coluccielo M, Ricketti AJ. Central serous chorioretinopathy secondary to corticosteroids in patients with atopic disease. Allergy Asthma Proc. 2015;36(2):123\u20139.","journal-title":"Allergy Asthma Proc."},{"issue":"7","key":"465_CR35","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/jdv.15608","volume":"33","author":"J Thyssen","year":"2019","unstructured":"Thyssen J, de Bruin-Weller M, Paller A, Leshem Y, Vestergaard C, Deleuran M, et al. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy\u2013International Eczema Council survey and opinion. J Eur Acad Dermatol Venereol. 2019;33(7):1224\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"24","key":"465_CR36","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"10","key":"465_CR37","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","volume":"154","author":"AD Treister","year":"2018","unstructured":"Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154(10):1208\u201311.","journal-title":"JAMA Dermatol."},{"key":"465_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869","author":"B Akinlade","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson E, Blauvelt A, Cork M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019. \nhttps:\/\/doi.org\/10.1111\/bjd.17869\n\n. (Epub 2019 Mar 9).","journal-title":"Br J Dermatol."},{"issue":"5","key":"465_CR39","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","volume":"6","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegraber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab\u2014clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6(5):1778\u20131780.e1.","journal-title":"J Allergy Clin Immunol Pract."},{"key":"465_CR40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ajoc.2017.06.017","volume":"7","author":"AC Barnes","year":"2017","unstructured":"Barnes AC, Blandford AD, Perry JD. Cicatricial ectropion in a patient treated with dupilumab. Am J Ophthalmol Case Rep. 2017;7:120\u20132.","journal-title":"Am J Ophthalmol Case Rep."},{"key":"465_CR41","first-page":"1","volume":"10","author":"MLM Yamane","year":"2019","unstructured":"Yamane MLM, Belsito DV, Glass LRD. Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis. Orbit. 2019;10:1\u20135.","journal-title":"Orbit."},{"issue":"12","key":"465_CR42","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","volume":"154","author":"RM Levine","year":"2018","unstructured":"Levine RM, Tattersall IW, Gaudio PA, King BA. Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management. JAMA Dermatol. 2018;154(12):1485\u20136.","journal-title":"JAMA Dermatol."},{"issue":"10039","key":"465_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31\u201344.","journal-title":"Lancet"},{"issue":"5","key":"465_CR44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","volume":"315","author":"C Bachert","year":"2016","unstructured":"Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469\u201379.","journal-title":"JAMA"},{"key":"465_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","volume":"54","author":"Z Ou","year":"2018","unstructured":"Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol. 2018;54:303\u201310.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"465_CR46","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","volume":"77","author":"JP Thyssen","year":"2017","unstructured":"Thyssen JP, Toft PB, Halling-Overgaard AS, Gislason GH, Skov L, Egeberg A. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol. 2017;77(2):280\u201386.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"465_CR47","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMc1700366","volume":"376","author":"M Mennini","year":"2017","unstructured":"Mennini M, Dahdah L, Fiocchi A. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis [letter]. N Engl J Med. 2017;376(11):1090.","journal-title":"N Engl J Med"},{"key":"465_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1533567","author":"E Shen","year":"2018","unstructured":"Shen E, Xie K, Jwo K, Smith J, Mosaed S. Dupilumab-induced follicular conjunctivitis. Ocular Immunol Inflammn. 2018. \nhttps:\/\/doi.org\/10.1080\/09273948.2018.1533567\n\n. (Epub 2018 Oct 18).","journal-title":"Ocular Immunol Inflammn."},{"issue":"5","key":"465_CR49","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/bjd.17538","volume":"180","author":"D Bakker","year":"2019","unstructured":"Bakker D, Ariens L, van Luijk C, van der Schaft J, Thijs J, Schuttelaar M, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis [letter]. Br J Dermatol. 2019;180(5):1248.","journal-title":"Br J Dermatol"},{"issue":"5","key":"465_CR50","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/bjd.16348","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Graham NMH, Pirozzi G, Shumel B. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Reply from the authors [letter]. Br J Dermatol. 2018;178(5):1220\u20131.","journal-title":"Br J Dermatol"},{"issue":"2","key":"465_CR51","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/1203475417743233","volume":"22","author":"M Gooderham","year":"2018","unstructured":"Gooderham M, McDonald J, Papp K. Diagnosis and management of conjunctivitis for the dermatologist. J Cutan Med Surg. 2018;22(2):200\u20136.","journal-title":"J Cutan Med Surg."},{"issue":"2","key":"465_CR52","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000328630","volume":"47","author":"MR Razeghinejad","year":"2012","unstructured":"Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2012;47(2):66\u201380.","journal-title":"Ophthalmic Res"},{"issue":"3","key":"465_CR53","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0002-9394(02)01982-7","volume":"135","author":"SM Rikkers","year":"2003","unstructured":"Rikkers SM, Holland GN, Drayton GE, Michel FK, Torres MF, Takahashi S. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol. 2003;135(3):297\u2013302.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"465_CR54","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/j.1365-2133.2007.08192.x","volume":"157","author":"DF Murrell","year":"2007","unstructured":"Murrell DF, Calvieri S, Ortonne JP, Ho VC, Weise-Riccardi S, Barbier N, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol. 2007;157(5):954\u20139.","journal-title":"Br J Dermatol"},{"issue":"s2","key":"465_CR55","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jdv.12445","volume":"28","author":"I Zschocke","year":"2014","unstructured":"Zschocke I, Mrowietz U, Karakasili E, Reich K. Non-adherence and measures to improve adherence in the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2014;28(s2):4\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"465_CR56","first-page":"Nc05","volume":"10","author":"RK Barot","year":"2016","unstructured":"Barot RK, Shitole SC, Bhagat N, Patil D, Sawant P, Patil K. Therapeutic effect of 0.1% tacrolimus eye ointment in allergic ocular diseases. J Clin Diagn Res. 2016;10(6):Nc05\u20139.","journal-title":"J Clin Diagn Res."},{"issue":"2","key":"465_CR57","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ajo.2013.10.006","volume":"157","author":"AM Al-Amri","year":"2014","unstructured":"Al-Amri AM. Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis. Am J Ophthalmol. 2014;157(2):280\u20136.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"465_CR58","first-page":"267","volume":"73","author":"AK Freeman","year":"2004","unstructured":"Freeman AK, Serle J, VanVeldhuisen P, Lind L, Clarke J, Singer G, et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis. 2004;73(4):267\u201371.","journal-title":"Cutis"},{"issue":"5","key":"465_CR59","first-page":"258","volume":"92","author":"SR Feldman","year":"2013","unstructured":"Feldman SR. Disease burden and treatment adherence in psoriasis patients. Cutis. 2013;92(5):258\u201363.","journal-title":"Cutis"},{"issue":"7","key":"465_CR60","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/sj.eye.6702367","volume":"21","author":"E Nivenius","year":"2007","unstructured":"Nivenius E, van der Ploeg I, Jung K, Chryssanthou E, van Hage M, Montan PG. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. Eye (Lond). 2007;21(7):968\u201375.","journal-title":"Eye (Lond)."},{"issue":"1","key":"465_CR61","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/jop.2011.0143","volume":"28","author":"Y Sakarya","year":"2012","unstructured":"Sakarya Y, Sakarya R. Treatment of refractory atopic blepharoconjunctivitis with topical tacrolimus 0.03% dermatologic ointment. J Ocul Pharmacol Ther. 2012;28(1):94\u20136.","journal-title":"J Ocul Pharmacol Ther."},{"issue":"2","key":"465_CR62","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.sder.2008.05.001","volume":"27","author":"M Boguniewicz","year":"2008","unstructured":"Boguniewicz M, Nicol N, Kelsay K, Leung DY. A multidisciplinary approach to evaluation and treatment of atopic dermatitis. Semin Cutan Med Surg. 2008;27(2):115\u201327.","journal-title":"Semin Cutan Med Surg"},{"issue":"3","key":"465_CR63","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000018497","volume":"201","author":"J L\u00fcbbe","year":"2000","unstructured":"L\u00fcbbe J, Pournaras CC, Saurat JH. Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology. 2000;201(3):249\u201351.","journal-title":"Dermatology."},{"issue":"5","key":"465_CR64","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jamadermatol.2013.7016","volume":"150","author":"V Kiiski","year":"2014","unstructured":"Kiiski V, Remitz A, Reitamo S, Mandelin J, Kari O. Long-term safety of topical pimecrolimus and topical tacrolimus in atopic blepharoconjunctivitis. JAMA Dermatol. 2014;150(5):571\u20133.","journal-title":"JAMA Dermatol."},{"issue":"4","key":"465_CR65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40662-017-0072-z","volume":"9","author":"SS Shoughy","year":"2017","unstructured":"Shoughy SS. Topical tacrolimus in anterior segment inflammatory disorders. Eye Vis (Lond). 2017;9(4):7.","journal-title":"Eye Vis (Lond)."},{"issue":"5","key":"465_CR66","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1089\/10807680260362696","volume":"18","author":"DS Small","year":"2002","unstructured":"Small DS, Acheampong A, Reis B, Stern K, Stewart W, Berdy G, et al. Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther. 2002;18(5):411\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"key":"465_CR67","first-page":"CD009078","volume":"9","author":"JJ Gonzalez-Lopez","year":"2012","unstructured":"Gonzalez-Lopez JJ, Lopez-Alcalde J, Morcillo Laiz R, Fernandez Buenaga R, Rebolleda Fernandez G. Topical cyclosporine for atopic keratoconjunctivitis. Cochrane Database Syst Rev. 2012;9:CD009078.","journal-title":"Cochrane Database Syst Rev."},{"issue":"8","key":"465_CR68","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1136\/bjophthalmol-2013-304453","volume":"98","author":"A Fukushima","year":"2014","unstructured":"Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, Kumagai N, et al. Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. Br J Ophthalmol. 2014;98(8):1023\u20137.","journal-title":"Br J Ophthalmol."},{"issue":"5","key":"465_CR69","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/ACI.0000000000000089","volume":"14","author":"N Erdinest","year":"2014","unstructured":"Erdinest N, Solomon A. Topical immunomodulators in the management of allergic eye diseases. Curr Opin Allergy Clin Immunol. 2014;14(5):457\u201363.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"11","key":"465_CR70","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/j.ophtha.2013.03.044","volume":"120","author":"KH Wan","year":"2013","unstructured":"Wan KH, Chen LJ, Rong SS, Pang CP, Young AL. Topical cyclosporine in the treatment of allergic conjunctivitis: a meta-analysis. Ophthalmology. 2013;120(11):2197\u2013203.","journal-title":"Ophthalmology"},{"key":"465_CR71","unstructured":"NEORAL (cyclosporine) [package insert]. East Hanover: Novartis Pharmaceuticals Corporation. 2015."},{"key":"465_CR72","unstructured":"SANDIMMUNE (cyclosporine) [package insert]. East Hanover: Novartis Pharmaceuticals Corporation. 2015."},{"key":"465_CR73","unstructured":"RESTASIS (cyclosporine ophthalmic emulsion) [package insert]. 0.05%. Irvine: Allergan. 2017."},{"issue":"2","key":"465_CR74","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jfo.2017.09.005","volume":"41","author":"F Rouimi","year":"2018","unstructured":"Rouimi F, Bouillot A, Baudouin C, Labbe A. Topical cyclosporine A and risk of ocular surface neoplasia [in French]. J Fr Ophtalmol. 2018;41(2):122\u20138.","journal-title":"J Fr Ophtalmol"},{"issue":"4","key":"465_CR75","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/BF00455039","volume":"216","author":"W Brenner","year":"1981","unstructured":"Brenner W, Grabner G. 3H-thymidine autoradiography of guinea pig cornea and skin after exposure to solar simulating radiation. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1981;216(4):319\u201325.","journal-title":"Albrecht Von Graefes Arch Klin Exp Ophthalmol."},{"issue":"2","key":"465_CR76","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.clindermatol.2014.10.017","volume":"33","author":"J De Pry","year":"2015","unstructured":"De Pry J, Brescoll J, Szczotka-Flynn L, Rambhatla P, Lim HW, Cooper K. Phototherapy-related ophthalmologic disorders. Clin Dermatol. 2015;33(2):247\u201355.","journal-title":"Clin Dermatol."},{"issue":"Suppl 3","key":"465_CR77","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1468-3083.2012.04520.x","volume":"26","author":"E Archier","year":"2012","unstructured":"Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maitre M, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):22\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"465_CR78","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","volume":"71","author":"R Sidbury","year":"2014","unstructured":"Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section\u00a03. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327\u201349.","journal-title":"J Am Acad Dermatol."},{"key":"465_CR79","first-page":"164","volume":"186","author":"PG Calzavara-Pinton","year":"1994","unstructured":"Calzavara-Pinton PG, Carlino A, Manfredi E, Semeraro F, Zane C, De Panfilis G. Ocular side effects of PUVA-treated patients refusing eye sun protection. Acta Derm Venereol Suppl (Stockh). 1994;186:164\u20135.","journal-title":"Acta Derm Venereol Suppl (Stockh)."},{"issue":"6","key":"465_CR80","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1365-2230.1989.tb02602.x","volume":"14","author":"AN Abdullah","year":"1989","unstructured":"Abdullah AN, Keczkes K. Cutaneous and ocular side-effects of PUVA photochemotherapy\u2014a 10-year follow-up study. Clin Exp Dermatol. 1989;14(6):421\u20134.","journal-title":"Clin Exp Dermatol"},{"key":"465_CR81","first-page":"235","volume":"66","author":"WB Glew","year":"1984","unstructured":"Glew WB, Nigra TP. Psoralens and ocular effects in humans. Natl Cancer Inst Monogr. 1984;66:235\u20139.","journal-title":"Natl Cancer Inst Monogr."},{"issue":"12","key":"465_CR82","first-page":"767","volume":"72","author":"SP Richer","year":"2001","unstructured":"Richer SP, Yonatan E, Harper CK, McNelis M, Rudy DR, Perdue A. A clinical review of non-age-related cataracts. Optometry. 2001;72(12):767\u201378.","journal-title":"Optometry."},{"issue":"5","key":"465_CR83","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/archdermatol.2010.411","volume":"147","author":"B Bair","year":"2011","unstructured":"Bair B, Dodd J, Heidelberg K, Krach K. Cataracts in atopic dermatitis: a case presentation and review of the literature. Arch Dermatol. 2011;147(5):585\u20138.","journal-title":"Arch Dermatol"},{"issue":"2","key":"465_CR84","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jaad.2007.04.027","volume":"57","author":"D Malanos","year":"2007","unstructured":"Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol. 2007;57(2):231\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"465_CR85","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/1523-1747.ep12276752","volume":"85","author":"RS Stern","year":"1985","unstructured":"Stern RS, Parrish JA, Fitzpatrick TB. Ocular findings in patients treated with PUVA. J Invest Dermatol. 1985;85(3):269\u201373.","journal-title":"J Invest Dermatol."},{"issue":"4","key":"465_CR86","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/1523-1747.ep12395733","volume":"103","author":"RS Stern","year":"1994","unstructured":"Stern RS. Ocular lens findings in patients treated with PUVA. Photochemotherapy follow-up-study. J Invest Dermatol. 1994;103(4):534\u20138.","journal-title":"J Invest Dermatol."},{"issue":"11","key":"465_CR87","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.4103\/ijo.IJO_413_17","volume":"65","author":"A Maitray","year":"2017","unstructured":"Maitray A, Rishi P. Methoxsalen-induced macular toxicity. Indian J Ophthalmol. 2017;65(11):1243\u20135.","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"465_CR88","first-page":"94","volume":"40","author":"S Soker","year":"2008","unstructured":"Soker S, Nergiz Y, Cakmak S, Bahceci S, Aytekin S. The demonstration of changes in bulbar conjunctiva surface epithelium in the psoriatic patients treated with PUVA. Ann Ophthalmol (Skokie). 2008;40(2):94\u20138.","journal-title":"Ann Ophthalmol (Skokie)."},{"issue":"15","key":"465_CR89","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1056\/NEJM199704103361501","volume":"336","author":"RS Stern","year":"1997","unstructured":"Stern RS, Nichols KT, V\u00e4kev\u00e4 LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med. 1997;336(15):1041\u20135.","journal-title":"N Engl J Med"},{"issue":"6","key":"465_CR90","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1755-3768.1993.tb08613.x","volume":"71","author":"G Haciyakupoglu","year":"1993","unstructured":"Haciyakupoglu G, Varinli I, Memisoglu HR, Varinli S, Demircan N, Denli G. PUVA treatment and choroidal malignant melanoma. Acta Ophthalmol (Copenh). 1993;71(6):846\u20139.","journal-title":"Acta Ophthalmol (Copenh)."},{"issue":"3","key":"465_CR91","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","volume":"75","author":"AS Paller","year":"2016","unstructured":"Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494\u2013503.e6.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"465_CR92","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/jop.2010.0084","volume":"27","author":"M Baeck","year":"2011","unstructured":"Baeck M, De Potter P, Goossens A. Allergic contact dermatitis following ocular use of corticosteroids. J Ocul Pharmacol Ther. 2011;27(1):83\u201392.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"465_CR93","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2310\/6620.2006.05048","volume":"17","author":"S Mimesh","year":"2006","unstructured":"Mimesh S, Pratt M. Allergic contact dermatitis from corticosteroids: reproducibility of patch testing and correlation with intradermal testing. Dermatitis. 2006;17(3):137\u201342.","journal-title":"Dermatitis."},{"issue":"2","key":"465_CR94","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jaad.2006.09.033","volume":"56","author":"DW Shaw","year":"2007","unstructured":"Shaw DW, Maibach HI, Eichenfield LF. Allergic contact dermatitis from pimecrolimus in a patient with tacrolimus allergy. J Am Acad Dermatol. 2007;56(2):342\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"465_CR95","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/0091-6749(94)90081-7","volume":"94","author":"SL Spector","year":"1994","unstructured":"Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol. 1994;94(1):134\u20136.","journal-title":"J Allergy Clin Immunol."},{"issue":"4","key":"465_CR96","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/IOP.0000000000000723","volume":"33","author":"SAM Chisholm","year":"2017","unstructured":"Chisholm SAM, Couch SM, Custer PL. Etiology and management of allergic eyelid dermatitis. Ophthalmic Plast Reconstr Surg. 2017;33(4):248\u201350.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"465_CR97","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2500\/aap.2012.33.3525","volume":"33","author":"L Bielory","year":"2012","unstructured":"Bielory L. Allergic conjunctivitis: the evolution of therapeutic options. Allergy Asthma Proc. 2012;33(2):129\u201339.","journal-title":"Allergy Asthma Proc."},{"issue":"4","key":"465_CR98","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.clinthera.2007.03.017","volume":"29","author":"GW Ousler","year":"2007","unstructured":"Ousler GW, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther. 2007;29(4):611\u20136.","journal-title":"Clin Ther"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00465-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-019-00465-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00465-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T19:09:46Z","timestamp":1595704186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-019-00465-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,27]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1007\/s40257-019-00465-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,27]]},"assertion":[{"value":"27 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article has no funding source.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kristen M. Beck, Gerami D. Seitzman, Eric J. Yang, and Isabelle M. Sanchez have no conflicts of interest to declare. Wilson Liao has received a research grant from\u00a0Sanofi\/Regeneron, which manufactures dupilumab. Sanofi\/Regeneron was not involved in the content, writing, or review of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work has not been previously presented.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}}]}}